This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").
Arecor Therapeutics plc
(“Arecor” or the “Company”)
Co-development Agreement with US Insulin Pump Device Company for AT278 and Sale of Royalty and Technology Access Fees for up to $11 million
08:30 - 10:00. Registration commences at 08:00
Join us for an interactive session, exploring the multiple benefits of Australian clinical trials.
Join Cambridge Network for a half-day workshop designed to help managers navigate leading teams made up of multiple generations. From Gen Z to Baby Boomers, each cohort brings their own unique strengths, values, and communication styles into the workplace. Learn how to bridge generational differences to build stronger, more collaborative, and higher-performing teams.
Fierce 15 highlights pre-commercial biotech companies driving the next generation of therapies for patients worldwide
Oxford, UK – 22nd September 2025. OGT, a leading global provider of genomic diagnostic and research solutions, announced today that the U.S. Food and Drug Administration (FDA) has granted their De Novo Classification Request for the CytoCell® KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic (CDx) for Syndax’s first-in-class menin inhibitor, REVUFORJ® (revumenib).
• Mohit Rawat appointed CEO, bringing deep biopharma leadership and a track record of driving innovations in drug discovery to commercial and transactional success; former CEO Robin Carr transitions to new CTO role
• Expanded senior team across clinical, CMC, regulatory and business development in the US and UK
• Global leader in developing a novel and highly differentiated payload class for ADCs, NMTi (N-myristoyltransferase inhibitors), to address the critical need to overcome payload resistance and improve tolerability
There are many different types of cells in the brain. We know that in Parkinson’s, brain cells that produce dopamine become damaged and start to die over time. However, it’s possible that other types of brain cells could also become damaged, and they may even play a role in why dopamine cells become unwell.
KRAS is one of the most frequently mutated oncogenes in human cancers. Once thought “undruggable,” recent scientific advances have enabled the development of therapies targeting KRAS mutations, especially G12C, G12D, and G13D.
At Medicilon, we provide integrated preclinical services to support KRAS-targeted drug discovery and development:
✅ Drug discovery
✅ CMC research (API + formulation)
✅ Pharmacodynamics study
✅ Pharmacokinetics (PK) analysis
✅ Safety evaluation
The Saez-Rodriguez Research Group
The goal of the Saez Rodriguez group is to acquire a functional understanding of the deregulation of signalling networks in disease and to apply this knowledge to develop novel therapeutics. We focus on cancer, auto-immune and fibrotic disease. Towards this goal, we integrate big (‘Omics’) data with mechanistic molecular knowledge into statistical and machine learning methods, and we share our tools as free open-source packages.
Your Role
Amsbio offers a growing list of experimental cell lines, recombinant proteins, and screening services to help accelerate the development of new CAR-T cell therapies. Personalized treatment for cancer reached a new milestone in 2017 with the FDA approval of CAR-T cell therapy for treatment of children and adolescents with B cell acute lymphoblastic leukemia (ALL).